# A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

> **NCT05470400** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 44 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** FP conjugate vaccine (25 mcg)
- **BIOLOGICAL:** FP conjugate vaccine (200 mcg)
- **BIOLOGICAL:** Trimer 6931 (100 mcg)
- **BIOLOGICAL:** Trimer 6931 (200 mcg)
- **BIOLOGICAL:** Trimer 4571 (200 mcg)
- **BIOLOGICAL:** Trimer 4571 (100 mcg)

## Key facts

- **NCT ID:** NCT05470400
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-15
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** The HVTN 303 IND was placed on clinical hold, and recruitment did not resume.
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470400, "A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05470400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*